CA3020418A1 - Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents - Google Patents

Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents Download PDF

Info

Publication number
CA3020418A1
CA3020418A1 CA3020418A CA3020418A CA3020418A1 CA 3020418 A1 CA3020418 A1 CA 3020418A1 CA 3020418 A CA3020418 A CA 3020418A CA 3020418 A CA3020418 A CA 3020418A CA 3020418 A1 CA3020418 A1 CA 3020418A1
Authority
CA
Canada
Prior art keywords
clever
macrophages
tnf
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3020418A
Other languages
English (en)
French (fr)
Inventor
Maija-Leena Hollmen
Miro VIITALA
Markku Jalkanen
Mikael Maksimow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of CA3020418A1 publication Critical patent/CA3020418A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3020418A 2016-04-18 2017-04-18 Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents Pending CA3020418A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20165336 2016-04-18
FI20165336 2016-04-18
PCT/FI2017/050286 WO2017182706A1 (en) 2016-04-18 2017-04-18 Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents

Publications (1)

Publication Number Publication Date
CA3020418A1 true CA3020418A1 (en) 2017-10-26

Family

ID=58692521

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020418A Pending CA3020418A1 (en) 2016-04-18 2017-04-18 Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents

Country Status (10)

Country Link
US (1) US10884000B2 (https=)
EP (1) EP3445786B1 (https=)
JP (2) JP7100588B2 (https=)
KR (1) KR102403660B1 (https=)
CN (1) CN109153720B (https=)
AU (1) AU2017252344B2 (https=)
BR (1) BR112018070350A2 (https=)
CA (1) CA3020418A1 (https=)
EA (1) EA201892313A1 (https=)
WO (1) WO2017182706A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210087454A (ko) 2018-11-01 2021-07-12 파론 파머수티컬스 오와이 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제
US20220404366A1 (en) * 2019-11-11 2022-12-22 Faron Pharmaceuticals Oy Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
WO2021214382A1 (en) * 2020-04-20 2021-10-28 Faron Pharmaceuticals Oy Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
JP2024545101A (ja) * 2021-12-07 2024-12-05 ファロン ファーマシューティカルズ オサケ ユキチュア 抗ｃｌｅｖｅｒ－１がん治療を誘導するための炎症マーカーの使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316106T2 (de) * 2002-01-09 2008-05-29 Faron Pharmaceuticals Oy Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung
FI20090161A0 (fi) 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
SG11201502827RA (en) 2012-11-09 2015-05-28 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.

Also Published As

Publication number Publication date
WO2017182706A1 (en) 2017-10-26
KR20180133854A (ko) 2018-12-17
JP2019521312A (ja) 2019-07-25
EP3445786C0 (en) 2023-10-04
JP7302049B2 (ja) 2023-07-03
EA201892313A1 (ru) 2019-03-29
EP3445786A1 (en) 2019-02-27
US10884000B2 (en) 2021-01-05
CN109153720A (zh) 2019-01-04
EP3445786B1 (en) 2023-10-04
AU2017252344B2 (en) 2023-12-21
JP2022065088A (ja) 2022-04-26
KR102403660B1 (ko) 2022-05-30
US20190064180A1 (en) 2019-02-28
JP7100588B2 (ja) 2022-07-13
CN109153720B (zh) 2022-10-21
BR112018070350A2 (pt) 2019-01-29
AU2017252344A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
JP7302049B2 (ja) Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断
AU2011317807B2 (en) Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
JP2021191765A (ja) Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用
JP7529754B2 (ja) がんを処置するための方法および組成物
EP3419643A1 (en) Smc combination therapy for the treatment of cancer
TWI847958B (zh) 用精胺酸耗盡劑進行之組合癌症免疫療法
Xia et al. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer
EP3500308A1 (en) Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema
US20060269526A1 (en) Stromal antigen-presenting cells and use thereof
EP3411049A1 (en) Methods of generating populations of tumour-infiltrating t cells
CN102898508B (zh) 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
HK1261998A1 (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
HK1261998B (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
CN116585315A (zh) 用于调节pd-1信号转导的组合物
US20160030558A1 (en) Enhancement of vaccines
WO2023167033A1 (ja) プロレニン受容体ペプチド、コンジュゲート、および医薬組成物
Jung et al. Synergistic Effect of Tolerogenic Dendritic Cells and Etanercept on a Collagen-induced Arthritis Animal Model
JPH08225462A (ja) ワクチン
EA043588B1 (ru) Лекарственное средство, содержащее рекомбинантные лектины омелы, для лечения опухолей головного мозга
BG66049B1 (bg) Средство за конкурентно инхибиране и/или блокиране на карциноембрионалния антиген /сеа/

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210602

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250630

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20251030

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260410

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260410

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20260413